{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:06:48Z","timestamp":1792415208988,"version":"4.4.0"},"reference-count":39,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109- 109-2320-B-400-019"],"award-info":[{"award-number":["MOST 109- 109-2320-B-400-019"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["IV-108-PP-17"],"award-info":[{"award-number":["IV-108-PP-17"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,9,13]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The major challenge of antitumor immunotherapy is dealing with the immunosuppressive tumor microenvironment, which involves immature myeloid cell accumulation that results in T cell dysfunction. Myeloid cell activation is induced by Toll-like receptor agonists. Additionally, granulocyte\/macrophage colony stimulating factor (GM-CSF) promotes myelopoiesis and recruits myeloid cells. Here, we combined the Toll-like receptor 2 (TLR2) agonist lipoprotein and GM-CSF to assess whether this bifunctional immunotherapy has synergistic effects on myeloid cells and could be further developed as a therapeutic intervention that enhances the antitumor response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the synergistic effects of biadjuvanted tumor antigen on antigen-presenting cell (APC) activation in bone marrow-derived dendritic cells. Furthermore, therapeutic efficacy was monitored in different tumor models treated via intratumoral or subcutaneous administration routes. The immune effects of the bifunctional fusion protein on myeloid cells in the tumor mass and draining lymph nodes were analyzed by flow cytometry. The induction of cytotoxic T lymphocytes was evaluated via intracellular cytokine levels, perforin\/granzyme B staining and an in vivo killing assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The TLR2 agonist lipoprotein combined with GM-CSF synergistically induced DC maturation, which subsequently enhanced antitumor immunity. In addition, rlipoE7m-MoGM modulated tumor-infiltrating myeloid cell populations. Vaccination with rlipoE7m-MoGM therapy increased the number of CCR7\n                      <jats:sup>+<\/jats:sup>\n                      CD103\n                      <jats:sup>+<\/jats:sup>\n                      cDC1s, whereas the number of suppressive tumor-associated macrophages was reduced in the tumor lesions. Consistent with this observation, proliferating antigen-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells are highly infiltrated within the tumor, and the expression of IFN-r and perforin was most pronounced within antigen-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in mice administered rlipoE7m-MoGM therapy. This finding corresponded with observation that the combination of a TLR2 agonist and GM-CSF provides increased antitumor activity by inhibiting established tumor outgrowth and protecting against metastatic cancer compared with a TLR2 agonist alone. Importantly, tumor growth inhibition was not due to the direct effects of the TLR2 agonist or GM-CSF but was instead due to the induction of antigen-specific immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of a TLR2 agonist and GM-CSF has synergistic effects that inhibit tumor growth and modulate tumor-infiltrating APCs. This therapeutic approach could be applied to other tumor antigens to treat different cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-002758","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T11:23:05Z","timestamp":1633087385000},"page":"e002758","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment"],"prefix":"10.1136","volume":"9","author":[{"given":"Wan-Lun","family":"Yan","sequence":"first","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Chieh","family":"Wu","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yin","family":"Shen","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan"},{"name":"School of Dentistry, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8736-1452","authenticated-orcid":false,"given":"Shih-Jen","family":"Liu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan"},{"name":"Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan"},{"name":"Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"2025100302565715000_9.10.e002758.1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100302565715000_9.10.e002758.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"2025100302565715000_9.10.e002758.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"2025100302565715000_9.10.e002758.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02388","article-title":"The role of TLRs in anti-cancer immunity and tumor rejection","volume":"10","author":"Urban-Wojciuk","year":"2019","journal-title":"Front Immunol"},{"key":"2025100302565715000_9.10.e002758.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040970"},{"key":"2025100302565715000_9.10.e002758.6","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-60","article-title":"Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy","volume":"13","author":"Chang","year":"2014","journal-title":"Mol Cancer"},{"key":"2025100302565715000_9.10.e002758.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.026"},{"key":"2025100302565715000_9.10.e002758.8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/imt-2016-0141","article-title":"Recent progress in GM-CSF-based cancer immunotherapy","volume":"9","author":"Yan","year":"2017","journal-title":"Immunotherapy"},{"key":"2025100302565715000_9.10.e002758.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.08.006"},{"key":"2025100302565715000_9.10.e002758.10","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2027"},{"key":"2025100302565715000_9.10.e002758.11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091844"},{"key":"2025100302565715000_9.10.e002758.12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302850"},{"key":"2025100302565715000_9.10.e002758.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.12.043"},{"key":"2025100302565715000_9.10.e002758.14","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/pmic.201000688","article-title":"Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis","volume":"11","author":"Kwok","year":"2011","journal-title":"Proteomics"},{"key":"2025100302565715000_9.10.e002758.15","doi-asserted-by":"publisher","DOI":"10.1038\/nri3712"},{"key":"2025100302565715000_9.10.e002758.16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190945"},{"key":"2025100302565715000_9.10.e002758.17","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","article-title":"Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling","volume":"13","author":"Tang","year":"2015","journal-title":"Cell Rep"},{"key":"2025100302565715000_9.10.e002758.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.01.008"},{"key":"2025100302565715000_9.10.e002758.19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020641"},{"key":"2025100302565715000_9.10.e002758.20","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-37"},{"key":"2025100302565715000_9.10.e002758.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3539"},{"key":"2025100302565715000_9.10.e002758.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0518"},{"key":"2025100302565715000_9.10.e002758.23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.vaccine.2015.02.019","article-title":"Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation","volume":"33","author":"Lee","year":"2015","journal-title":"Vaccine"},{"key":"2025100302565715000_9.10.e002758.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0198-7"},{"key":"2025100302565715000_9.10.e002758.25","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700453"},{"key":"2025100302565715000_9.10.e002758.26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0041"},{"key":"2025100302565715000_9.10.e002758.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.007"},{"key":"2025100302565715000_9.10.e002758.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.03.003"},{"key":"2025100302565715000_9.10.e002758.29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60659"},{"key":"2025100302565715000_9.10.e002758.30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.imbio.2018.10.007","article-title":"Granulocyte macrophage-colony stimulating factor: a key modulator of renal mononuclear phagocyte plasticity","volume":"224","author":"Mylonas","year":"2019","journal-title":"Immunobiology"},{"key":"2025100302565715000_9.10.e002758.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003"},{"key":"2025100302565715000_9.10.e002758.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012"},{"key":"2025100302565715000_9.10.e002758.33","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0149"},{"key":"2025100302565715000_9.10.e002758.34","article-title":"Gm-Csf quantity has a selective effect on granulocytic vs. monocytic myeloid development and function","volume":"2018","author":"Sun","year":"1922","journal-title":"Front Immunol"},{"key":"2025100302565715000_9.10.e002758.35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419762"},{"key":"2025100302565715000_9.10.e002758.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5245"},{"key":"2025100302565715000_9.10.e002758.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0869"},{"key":"2025100302565715000_9.10.e002758.38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01563"},{"key":"2025100302565715000_9.10.e002758.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215020"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:57:05Z","timestamp":1759485425000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,1]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/jitc-2021-002758"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002758","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}